Leerink Partnrs Has Positive Outlook of REGN Q4 Earnings
Investment analysts at Leerink Partnrs increased their Q4 2024 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, January 28th. Leerink Partnrs analyst ...
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.48% to $672.98 Friday, on what proved to be an all-around grim ...
Zacks.com on MSN12h
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...
Limerick Leader12h
PICTURES: Regeneron Great Limerick Run launched by Marty Morrissey and Minister Patrick O'Donovan
All the latest breaking local news from Limerick and County Limerick Please allow ads as they help fund our trusted local ...
Bernstein cuts Regeneron stock price target to $1,000, keeps Outperform
Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.
Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Regeneron (REGN) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...